This is the sixth S-1 amendment for the same ELOC resale registration, indicating a prolonged effort to get the registration effective. Monitor for the SEC declaring the registration effective, which would allow RH2 to begin selling shares and create persistent selling pressure. The company's plan to limit draws to $1M unless the stock exceeds $1 provides a ceiling on near-term dilution but does not eliminate the overhang.
Executive Summary
CTT Pharmaceutical Holdings filed Amendment No. 6 to its S-1 registration statement, registering 6,250,000 shares for resale by RH2 Equity Partners under an Equity Line of Credit (ELOC) agreement. The company is a development-stage pharmaceutical firm with no revenue, a history of losses, a going-concern qualification, and only $7,089 cash on hand. The ELOC provides up to $10 million in potential funding, but at the current $0.08 stock price, full issuance of the registered shares would yield only ~$500,000, and the company plans to limit draws to $1 million unless the stock exceeds $1, continuing the dilution risk for existing shareholders.
Key Facts
- CTT Pharmaceutical Holdings filed Amendment No. 6 to its S-1, registering 6,250,000 shares for resale by RH2 Equity Partners under an ELOC.
- The company is a development-stage pharmaceutical firm with no revenue, a history of losses, and a going-concern qualification from its auditors.
- As of March 31, 2026, the company had only $7,089 cash on hand and an accumulated deficit of $7,636,137.
- The ELOC provides up to $10 million in potential funding, but at the current $0.08 stock price, full issuance of the registered shares would yield only ~$500,000.
- The company plans to limit draws to $1 million unless the stock price exceeds $1 per share, but no assurance is given that such price levels will occur.
- The purchase price for shares sold to RH2 under the ELOC is 85% of the lowest daily VWAP during the ten business days prior to the purchase notice.
- Officers and directors collectively own approximately 51.1% of the outstanding common stock.
- The company has identified material weaknesses in its internal controls over financial reporting.
- The company has signed a LOI with a European company for a potential partnership, but discussions are in early stages.
- The company received approval for a Continuation-in-Part (CIP) patent application from the U.S. Patent Office in April 2026 for its nicotine strip technology.
Financial Impact
Development-stage company with no revenue, $7,089 cash, and a $7.6M accumulated deficit. The ELOC provides up to $10M in potential funding, but at current prices, full issuance of registered shares would yield ~$500K. Net loss was $84,674 in Q1 2026.
Risk Factors
- Going-concern risk with only $7,089 cash and no revenue.
- Massive dilution risk from the ELOC; at current $0.08 price, raising $1M would require ~12.5M new shares (21% dilution).
- No FDA approval for nicotine strips; regulatory pathway uncertain and costly.
- Material weaknesses in internal controls over financial reporting.
- Penny stock status limits liquidity and institutional interest.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-1/A Filing (CTTH) — Batch item 1 | 0001171520-26-000192 |
| Exhibit: ex23-1.htm | 0001171520-26-000192 |
| Document: 0001171520-26-000192-index-headers.html | 0001171520-26-000192 |
| Document: 0001171520-26-000192-index.html | 0001171520-26-000192 |
| Document: 0001171520-26-000192.txt | 0001171520-26-000192 |
| S-1/A Filing (CTTH) — Batch item 6 | 0001171520-26-000192 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 9, 2026 18d ago | 8-K | $0.0566 | awaiting T+60 | — | $0.0570 (+0.71%) |
Oct 7, 2026 19d ago | 8-K | $0.0566 | awaiting T+60 | — | $0.0570 (−0.71%) |
Aug 12, 2026 10w ago | 8-K | $0.0660 | awaiting T+60 | — | $0.0570 (−13.64%) |
Jul 24, 2026 13w ago | S-1/A | $0.0660 $0.0589 | ▲ +10.76% | ▲ +14.31% | $0.0570 (+13.64%) |
Jun 29, 2026 17w ago | S-1/A | $0.0750 $0.0485 | ▲ +35.33% | ▲ +38.38% | $0.0570 (+24.00%) |
Jun 16, 2026 19w ago | S-1/A | $0.0800 $0.0518 | ▲ +35.25% | ▲ +38.66% | $0.0570 (+28.75%) |
May 29, 2026 21w ago | S-1/A | $0.0720 $0.0570 | ▲ +20.83% | ▲ +22.02% | $0.0570 (+20.83%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers